Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Protein A 42-kDa is a chemical component found in the cell wall of staphylococcus aureus and finds application in biotechnological industry. It is composed of five immunoglobulin-binding domains, each of which are able to bind proteins from many mammalian species, most notably Immunoglobulin G (IgG). Protein A is most frequently used in bio manufacturing as it is very robust purification procedure and is used as a capture step due to its specificity. The factors influencing growth, including the number of monoclonal antibodies (mAbs) in development and clinical trials, biosimilar developments, and facility expansions using single-use strategies. Also, due to high specificity and affinity of protein A resins, 99% of purity can be achieved in most generic form.
The driving factors for growth of protein a resin market increasing demand for therapeutic antibodies as protein A resin for monoclonal antibody purification demonstrate high dynamic binding performance at low flow rates maintaining superior binding capacity at high linear velocities. Also, growing demand for disposable pre-packed columns since it is major used for downstream bioprocessing. The increasing requirement for productivity and efficiency single -use and flexible facilities are fueling the growth. Moreover, increasing pharmaceutical R&D spending innovative products is propelling the market growth. Beside emergence of disease like cancer and other is expected to lead the growth of global protein A resin market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the protein a resin market. In addition, complete analysis of changes on the protein a resin market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 impact on the protein a resin market was moderate for few months due to pandemic. In addition, production and supply chain disruption has hampered the growth of market
The protein a resin market is segmented based on by product, by matrix type, by application, by end user and geography
The protein a resin are available in different product types including natural protein A, recombinant protein A. Recombinant protein A leads in the protein a resin market attributed to improving solubility and to normalise sensitivity of alkaline solutions. Also, increasing technological advancements and expanding pharmaceuticals industry for innovative drug development is propelling the segment growth
Depending on matrix type protein a resin includes agarose-based, glass/silica-based, organic polymer-based protein A. Agarose-based is expected to hold largest market share in protein a resin owing to major used matrix resin for the attachment of ligands that bind protein. The high gelling strength at low concentrations with suitable pH range and superior mechanical strength has witness optimistic growth.
The protein a resin had its major applications in antibody purification and immuno precipitation. The antibody purification is expected to hold significant market in protein a resin market attributed to growing demand for therapeutic as well as research purposes which further driving the demand of protein a resin. Also, monoclonal antibody (mAb) purification is Protein A affinity chromatography, a technology that has gained high interest because of its great performance and capabilities.
The protein a resin had end user in pharmaceutical, biopharmaceutical companies, clinical research laboratories. Pharmaceutical followed by Biopharmaceutical companies is projected to significant market share in global protein a resin market. The protein A resin is a well-known in pharmaceutical process because of high binding affinity and the purity levels which can be obtained. The purification process consists on loading the clarified cell culture containing the target antibodies as neutal pH on the immobilized Protein A support, allowing the interaction between the ligands. Also, increasing research and development of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of the segment. Moreover, manufacturers recycle the resin over an extended period often stretching their use for more than 100–200 cycles. These Protein A-resins are exhaustively utilized for the purification of mAbs which is enhancing the growth of biopharmaceutical companies ultimately fueling the growth of global protein a resin market.
Geographically the global protein a resin market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). By geography North America is anticipated to dominate in the global protein a resin market due to presence of key players in the regions. In addition increasing investments in research and development by key players is propelling the regional growth. Moreover, increasing incidence of chronic diseases and rising autoimmune and orphan diseases has major demand for better treatment methods which is further boosting market growth in the region. On the other hand Asia Pacific is expected to grow at highest pace owing to presence of major pharmaceutical and biopharmaceutical research companies. Also, growth is attributed to increasing research and development in region.
The key players in protein a resin market are GE Healthcare, Merck Millipore, Repligen Corporation, Thermo Fisher Scientific, Tosoh Bioscience , Purolite Corporation, Novasep Holding SAS, Agilent Technologies , GenScript Biotech Corporation, PerkinElmer , Bio-Rad Laboratories , Orochem , Kaneka Corporation , Abcam , Agarose Bead Technologies , Bio-Works Technologies , Purolite Life Sciences and Expedeon Ltd. among others.
November 2019: Purolite resin had been booming on biopharma uptake and ‘major’ regulatory milestone. The US FDA had approved a manufacturing process using a Purolite Praesto resin. Purolite says Janssen, Celgene and Biogen are among the firms working with its Praesto range of mAb capture resins.
June 2018: Purolite had launched New Protein A Resin. The resulting of new agarose-based Protein A resin delivers better performance in terms of capacity, pressure flow, and lifetime, according to the company. In addition, in-process risks and cross-contamination are managed effectively.
The report analyses the global protein a resin market based on by product, by matrix type, by application, by end user and geography. The protein a resin are available in different product types including natural protein A, recombinant protein A. Depending on matrix type protein a resin includes agarose-based, glass/silica-based, organic polymer-based protein A. The protein a resin had its major applications in antibody purification and immuno precipitation. The protein a resin had end user in pharmaceutical, biopharmaceutical companies, clinical research laboratories. Geographically the global protein a resin market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW)
The key players in protein a resin market are GE Healthcare, Merck Millipore, Repligen Corporation, Thermo Fisher Scientific, Tosoh Bioscience , Purolite Corporation, Novasep Holding SAS, Agilent Technologies , GenScript Biotech Corporation, PerkinElmer , Bio-Rad Laboratories , Orochem , Kaneka Corporation , Abcam , Agarose Bead Technologies , Bio-Works Technologies , Purolite Life Sciences and Expedeon Ltd. among others.
Why to buy this report:
